Atty Dkt. No.: STAN-316 USSN: 10/528,377

AMENDMENTS TO THE CLAIMS:

Please amend the claims as shown below. A complete listing of the claims, including their current status identifier, is set forth below.

- 1. (Currently Amended) A method comprising:
- contacting a hepatitis C virus (HCV) NS4B nucleotide binding motif (NBM)

polypeptide NS4B protein with a candidate agent and HCV RNA; and

determining an effect of said candidate agent on on:

- (i) a GTPase activity or a nucleotide binding activity of said NS4B protein polypeptide; and
- (ii) an HCV RNA binding activity of said NS4B protein.

 determining an effect of said candidate agent on replication of HCV.
- 2-5. (Canceled)
- 6. (Original) The method of claim 1, wherein said candidate agent is a nucleotide analog.
- 7. (Original) The method of claim 6, wherein said nucleotide analog is a non-hydrolysable nucleotide.
 - 8. (Canceled).
- 9. (**Currently Amended**) The method of <u>claim 24</u> <u>claim 1</u>, wherein said HCV is a subgenomic or full length HCV replicon.
- 10. (**Currently Amended**) The method of <u>claim 24, claim 1</u> wherein said method comprises determining an effect of said candidate agent on HCV replication in a huh7 cell.
 - 11-21. (Canceled)

Atty Dkt. No.: STAN-316 USSN: 10/528,377

22. (**Currently Amended**) The method of <u>claim 24, claim 1</u> wherein said method comprises assaying said candidate agent on HCV replication in a liver cell line or primary liver cell.

- 23. (**Currently Amended**) The method of claim 9, wherein said HCV is live virus or a replicon thereof.
- 24. (New) The method of claim 1, further comprising determining an effect of said candidate agent on replication of HCV.